Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03422679
Other study ID # CB103-C-101
Secondary ID
Status Terminated
Phase Phase 1/Phase 2
First received
Last updated
Start date December 5, 2017
Est. completion date November 11, 2022

Study information

Verified date January 2024
Source Cellestia Biotech AG
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase I/II, non randomized, open-label, dose escalation study to investigate the safety, tolerability and preliminary efficacy of CB-103.


Description:

This Phase I/IIA, open label, multicenter, dose escalation study of CB-103 in patients with Locally Advanced or Metastatic Solid Tumours and Haematological Malignancies. After providing signed informed consent, patients will be screened for entry into the study. The study will be conducted in 2 stages: dose escalation in Part A of the study (Phase I) followed by dose expansion in Part B (Phase IIA). Escalation cohorts will receive repeat doses of CB-103 to determine the MTD and RP2D. CB-103 will be administered orally in treatment cycles of 28-days each. Aim of the expansion Phase IIA, Part B of the study will be to collect preliminary evidence of anti-tumour activity.


Recruitment information / eligibility

Status Terminated
Enrollment 79
Est. completion date November 11, 2022
Est. primary completion date November 11, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility INCLUSION CRITERIA: 1. Disease - Patients with histologically or cytologically confirmed solid tumours (breast cancer (triple negative breast cancer [TNBC], ER+/-, HER2+/-), gastrointestinal (GI) cancers (resistant to oxaliplatin or irinotecan-based therapy colorectal cancer [CRC]), osteosarcoma, adenoid cystic carcinoma (ACC), and malignant glomus tumour) that are surgically unresectable, locally advanced, or metastatic and whose disease has progressed on at least one line of systemic therapy (with the exception of ACC patients who are allowed to be systemic treatment-naïve) and for whom no established therapeutic alternatives exist. Any other solid cancer (including lymphoma) with a confirmed NOTCH1-4 activating mutation or genetic lesion. - Relapsed or refractory (r/r) T-cell acute lymphoblastic leukaemia (T-ALL) or lymphoma (T-LBL) with a confirmed NOTCH pathway activation. Refractory patients are defined as T-ALL/T-LBL patients with = 5% bone marrow blasts, and/or concomitant extramedullary involvement, who have not achieved a CR after standard induction/consolidation therapy attempt. 2. Demography: men and women = 18 years old 3. Adequate organ function and laboratory results 4. Adequate contraceptive measures 5. Signed informed consent EXCLUSION CRITERIA 1. Medical History 1. Patients with symptomatic CNS metastases (neurologically unstable or requiring increasing doses of steroids to control their CNS disease) 2. Hypersensitivity to any of the excipients of CB-103 3. Patients with unresolved nausea, vomiting, or diarrhoea of CTCAE grade > 1 4. Impairment of GI function or presence of GI disease that may significantly alter the absorption of CB-103 5. History of second or other primary cancer with the exception of: - Curatively treated non-melanomatous skin cancer - Curatively treated cervical cancer or breast carcinoma in situ - Other primary solid tumour treated with curative intent and no known active disease present and no treatment administered during the last 2 years. 2. Exclusionary concurrent medical conditions Impaired cardiac function or clinically significant cardiac diseases. 3. Prior Therapy - In patients with solid tumours cytotoxic chemotherapy within 3 weeks - In T-ALL/T-LBL patients, prior anticancer therapy less than 2 weeks prior to starting therapy or 5 half-lives (whichever is longer) with exceptions. - Radiation therapy within 2 weeks of scheduled CB-103 dosing day 1 - Immunotherapy, biological therapies, targeted small molecules, hormonal therapies within 3 weeks of scheduled CB-103 dosing day 1 - Unresolved toxicity CTCAE grade > 1 from previous anti-cancer therapy or radiotherapy (excluding neurotoxicity, alopecia, ototoxicity, lymphopenia), or incomplete recovery from previous surgery.

Study Design


Intervention

Drug:
CB-103
Hard gelatine capsules taken orally during treatment period. Treatment cycle is 28 days.

Locations

Country Name City State
France Centre Hospitalier Lyon-Sud Lyon
France Hôpital Saint-Louis Paris
Germany Charite- Universitaetsmedizin Berlin- Campus Benjamin Franklin Berlin
Germany Universitätsklinikum Frankfurt Frankfurt
Germany Nationales Centrum für Tumorerkrankungen Heidelberg Heidelberg
Korea, Republic of Seoul National University Hospital Seoul
Korea, Republic of Seoul National University Hospital Seoul
Korea, Republic of Severance Hospital - Yonsei Cancer Center Seoul
Spain Catalan Institute of Oncology Barcelona
Spain Hospital Quirón Barcelona Barcelona
Spain Vall d'Hebron Institute of Oncology (VHIO) Barcelona
Spain Hospital Ramón y Cajal Madrid
Switzerland Oncology Institute of Southern Switzerland Bellinzona
Switzerland Kantonsspital St.Gallen Saint Gallen
United States Dana-Farber Cancer Institute Boston Massachusetts
United States MD Anderson Houston Texas
United States Sarcoma Oncology Research Center Santa Monica California

Sponsors (1)

Lead Sponsor Collaborator
Cellestia Biotech AG

Countries where clinical trial is conducted

United States,  France,  Germany,  Korea, Republic of,  Spain,  Switzerland, 

References & Publications (1)

Hanna GJ, Stathis A, Lopez-Miranda E, Racca F, Quon D, Leyvraz S, Hess D, Keam B, Rodon J, Ahn MJ, Kim HR, Schneeweiss A, Ribera JM, DeAngelo D, Perez Garcia JM, Cortes J, Schonborn-Kellenberger O, Weber D, Pisa P, Bauer M, Beni L, Bobadilla M, Lehal R, Vigolo M, Vogl FD, Garralda E. A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors. Cancer Res Commun. 2023 Sep 14;3(9):1853-1861. doi: 10.1158/2767-9764.CRC-23-0333. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Dose Limiting Toxicity (DLT) Number of patients with dose limiting toxicity during the first cycle.
DLT is defined as a severe adverse event or abnormal laboratory value assessed as unrelated to disease progression, inter-current illness, or concomitant medications, that occurs = 28 days following the first dose of CB-103 (Cycle 1).
28 days
Secondary Overall Response Rate Number of patients with an overall response rate (CR+PR assessed by RECSIT v1.1 or CR or CRi by NCCN guidelines) up to 24 months 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A